Key Points
- Endurance (Cayman) Ltd Svf sold 235,971 shares of Vir Biotechnology on Nov. 25 at an average price of $6.38 for about $1.505 million, reducing its stake by 1.64% to 14,110,209 shares (≈$90.0M).
- The Nov. 25 sale is part of a string of disposals by Endurance in Oct–Nov that total about 1.24 million shares, indicating sustained large-scale selling by the major shareholder.
- Separately, Vir reported a quarterly EPS loss of $1.17 (missing estimates), very low revenue and negative margins; the stock has a market cap of roughly $889M and a consensus analyst target of $17.30.
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) major shareholder Endurance (Cayman) Ltd Svf sold 227,803 shares of the company's stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $6.15, for a total transaction of $1,400,988.45. Following the completion of the sale, the insider directly owned 14,346,180 shares in the company, valued at approximately $88,229,007. The trade was a 1.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
Endurance (Cayman) Ltd Svf also recently made the following trade(s):
- On Tuesday, November 25th, Endurance (Cayman) Ltd Svf sold 235,971 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.38, for a total value of $1,505,494.98.
- On Wednesday, October 29th, Endurance (Cayman) Ltd Svf sold 100 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.49, for a total value of $649.00.
- On Tuesday, October 28th, Endurance (Cayman) Ltd Svf sold 24,453 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.50, for a total value of $158,944.50.
- On Monday, October 27th, Endurance (Cayman) Ltd Svf sold 66,403 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.05, for a total value of $401,738.15.
- On Friday, October 24th, Endurance (Cayman) Ltd Svf sold 46,696 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.96, for a total transaction of $278,308.16.
- On Thursday, October 23rd, Endurance (Cayman) Ltd Svf sold 154,383 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.99, for a total transaction of $924,754.17.
- On Wednesday, October 22nd, Endurance (Cayman) Ltd Svf sold 144,266 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.15, for a total transaction of $887,235.90.
- On Tuesday, October 21st, Endurance (Cayman) Ltd Svf sold 109,675 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.30, for a total transaction of $690,952.50.
- On Monday, October 20th, Endurance (Cayman) Ltd Svf sold 220,535 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.20, for a total value of $1,367,317.00.
- On Thursday, October 16th, Endurance (Cayman) Ltd Svf sold 12,844 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.10, for a total value of $78,348.40.
Vir Biotechnology Stock Performance
VIR stock opened at $6.39 on Thursday. Vir Biotechnology, Inc. has a 52 week low of $4.16 and a 52 week high of $14.45. The company's 50-day simple moving average is $5.71 and its 200 day simple moving average is $5.28. The company has a market capitalization of $888.98 million, a PE ratio of -1.77 and a beta of 1.27.
Vir Biotechnology (NASDAQ:VIR - Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.47). Vir Biotechnology had a negative net margin of 2,963.54% and a negative return on equity of 50.76%. The business had revenue of $0.24 million during the quarter, compared to the consensus estimate of $1.98 million. During the same period in the prior year, the firm earned ($1.56) EPS. The business's revenue for the quarter was up .8% on a year-over-year basis. On average, analysts forecast that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.
Hedge Funds Weigh In On Vir Biotechnology
A number of institutional investors have recently added to or reduced their stakes in VIR. Raymond James Financial Inc. acquired a new stake in Vir Biotechnology in the second quarter valued at approximately $35,000. Federated Hermes Inc. increased its stake in shares of Vir Biotechnology by 153.8% in the third quarter. Federated Hermes Inc. now owns 8,085 shares of the company's stock valued at $46,000 after buying an additional 4,899 shares during the period. Apollon Wealth Management LLC bought a new position in Vir Biotechnology in the 2nd quarter valued at approximately $50,000. Daiwa Securities Group Inc. boosted its position in Vir Biotechnology by 2,200.6% during the 2nd quarter. Daiwa Securities Group Inc. now owns 12,308 shares of the company's stock worth $62,000 after buying an additional 11,773 shares during the period. Finally, Los Angeles Capital Management LLC acquired a new stake in Vir Biotechnology during the 2nd quarter worth approximately $63,000. 65.32% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities analysts have weighed in on the company. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Vir Biotechnology in a report on Monday. HC Wainwright reiterated a "buy" rating and set a $15.00 price objective on shares of Vir Biotechnology in a research note on Monday, September 15th. Evercore ISI began coverage on shares of Vir Biotechnology in a report on Wednesday, September 3rd. They issued an "outperform" rating and a $12.00 target price on the stock. Finally, Bank of America raised shares of Vir Biotechnology from a "neutral" rating to a "buy" rating and upped their price target for the stock from $12.00 to $14.00 in a report on Wednesday, August 27th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $17.30.
View Our Latest Stock Analysis on VIR
About Vir Biotechnology
(
Get Free Report)
Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
